{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:13Z","timestamp":1792427773145,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03184-w","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:33:08Z","timestamp":1745310788000},"page":"2679-2689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma"],"prefix":"10.1007","volume":"42","author":[{"suffix":"Jr.","given":"Reynold A.","family":"Panettieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-8994","authenticated-orcid":false,"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-704X","authenticated-orcid":false,"given":"Andrew W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Shelkrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-7336","authenticated-orcid":false,"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"3184_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105919","volume":"165","author":"M Engelkes","year":"2020","unstructured":"Engelkes M, de Ridder MA, Svensson E, Berencsi K, Prieto-Alhambra D, Lapi F, et al. Multinational cohort study of mortality in patients with asthma and severe asthma. Respir Med. 2020;165:105919.","journal-title":"Respir Med"},{"issue":"3","key":"3184_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.anai.2021.03.015","volume":"127","author":"J Reibman","year":"2021","unstructured":"Reibman J, Tan L, Ambrose C, Chung Y, Desai P, Llanos JP, et al. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318\u201325.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"3184_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.anai.2021.07.010","volume":"127","author":"J Trevor","year":"2021","unstructured":"Trevor J, Lugogo N, Carr W, Moore WC, Soong W, Panettieri RA Jr., et al. Severe asthma exacerbations in the United States: incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy Asthma Immunol. 2021;127(5):579\u201387.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"3184_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1080\/03007995.2018.1505352","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075\u201388.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"3184_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1185\/030079908X280518","volume":"24","author":"NS Breekveldt-Postma","year":"2008","unstructured":"Breekveldt-Postma NS, Erkens JA, Aalbers R, van de Ven MJ, Lammers JW, Herings RM. Extent of uncontrolled disease and associated medical costs in severe asthma: a PHARMO study. Curr Med Res Opin. 2008;24(4):975\u201383.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"3184_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jaip.2024.01.023","volume":"12","author":"A Bourdin","year":"2024","unstructured":"Bourdin A, Brusselle G, Couillard S, Fajt ML, Heaney LG, Israel E, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract. 2024;12(4):809\u201323.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3184_CR7","unstructured":"GlaxoSmithKline. NUCALA (mepolizumab) Prescribing Information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125526Orig1s021,761122Orig1s011Corrected_lbl.pdf (Accessed Aug 5, 2024)."},{"key":"3184_CR8","unstructured":"Regeneron. DUPIXENT (dupilumab) Prescribing Information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761055s059lbl.pdf (Accessed Aug 5, 2024)."},{"key":"3184_CR9","unstructured":"AstraZeneca. FASENRA (benralizumab) Prescribing Information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070Orig1s020correctedlbl.pdf (Accessed Aug 5, 2024)."},{"key":"3184_CR10","unstructured":"Teva. CINQAIR (reslizumab) Prescribing Information. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/0761033s010lbl.pdf (Accessed Aug 5, 2024)."},{"key":"3184_CR11","unstructured":"Genentech. XOLAIR (omalizumab) Prescribing Information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103976s5245lbl.pdf (Accessed Aug 5, 2024)."},{"key":"3184_CR12","unstructured":"AstraZeneca. TEZSPIRE (tezepelumab) Prescribing Information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761224s003lbl.pdf (Accessed Aug 5, 2024)."},{"issue":"10056","key":"3184_CR13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115\u201327.","journal-title":"Lancet"},{"issue":"26","key":"3184_CR14","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"3184_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3184_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390\u2013400.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3184_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.anai.2020.05.020","volume":"125","author":"J Corren","year":"2020","unstructured":"Corren J, Chen S, Callan L, Gil EG. The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. Ann Allergy Asthma Immunol. 2020;125(2):211\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"3184_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936\u201346.","journal-title":"N Engl J Med"},{"issue":"10056","key":"3184_CR19","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341.","journal-title":"Lancet"},{"issue":"19","key":"3184_CR20","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139.","journal-title":"N Engl J Med"},{"issue":"13","key":"3184_CR21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"9842","key":"3184_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"key":"3184_CR23","unstructured":"Global Initiative for Asthma. Global Strategy for asthma management and prevention. 2023. Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2023\/05\/GINA-2023-Full-Report-2023-WMS.pdf (Accessed Jun 13, 2024)."},{"issue":"3","key":"3184_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7414","key":"3184_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"3184_CR26","unstructured":"Global Initiative for Asthma. Global Strategy for asthma management and prevention. 2024. Available from: https:\/\/ginasthma.org\/2024-report\/ (Accessed Jun 13, 2024)."},{"issue":"172","key":"3184_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0238-2023","volume":"33","author":"C Kyriakopoulos","year":"2024","unstructured":"Kyriakopoulos C, Gogali A, Markozannes G, Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev. 2024;33(172): 230238.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"3184_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790\u2013804.","journal-title":"Chest"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03184-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03184-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03184-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:00:24Z","timestamp":1747468824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03184-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3184"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03184-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reynold A. Panettieri Jr. has received research support from ACTIV-1, Agomab Therapeutics, AstraZeneca, Janssen Pharmaceuticals, the Research Institute for Fragrance Materials, Teva Pharmaceuticals, and Vault Health; has served as a consultant\/advisory board member for AstraZeneca, Genentech, Praesidia Biotherapeutics, and the Research Institute for Fragrance Materials; and has received speaker fees from AstraZeneca, Merck Group, and Sanofi. Monica Kraft has received research support from the American Lung Association, AstraZeneca, Janssen, the National Institutes of Health, Sanofi, and Synairgen with funds paid to the Icahn School of Medicine and University of Arizona and has received personal fees from AstraZeneca, Chiesi, Genentech, Kinaset Therapeutics, and Sanofi. Mario Castro has received grants\/research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, the National Institutes of Health, Novartis, the Patient-Centered Outcomes Research Institute, PULMATRiX, Sanofi-Aventis, Shionogi, and Theravance Biopharma; consultancy fees from Allakos, Amgen, Arrowhead, AstraZeneca, Genentech, Merck, Novartis, OM Pharma, Pioneering Medicines, Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals; and royalties from Aer Therapeutics. Magdalena Bober, Max Shelkrot and Christopher S. Ambrose are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Andrew W. Lindsley is an employee of Amgen and owns stock in Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}